Monday, September 30, 2013
• Bioheart Inc., of Sunrise, Fla., reported preliminary data from its Phase I ANGEL trial, showing at the three-month time point that patients are demonstrating an average improvement in exercise capacity or a six-minute walk test of 47 meters.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.